Report cover image

Global Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2030

Publisher Data Bridge Market Research
Published Oct 01, 2023
Length 343 Pages
SKU # DAABD18360488

Description

Global Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2030


The global duchenne muscular dystrophy treatment market is expected to reach USD 8,654,688.51 thousand by 2030 from USD 2,595,090.00 thousand in 2022, growing at a CAGR of 16.8% in the forecast period of 2023 to 2030.
Market Segmentation
Global Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030

Overview of Global Duchenne Muscular Dystrophy Treatment Market Dynamics

Driver
• Increasing prevalence and impact of Duchenne Muscular Dystrophy (DMD) disease

Restraint

• High treatment cost of DMD disorder

Opportunity

• Strategic initiatives by key market players

Market Players

Some of the key market players for global duchenne muscular dystrophy treatment market are:

• Sarepta Therapeutics, Inc.
• Solid Biosciences Inc.
• Capricor Therapeutics, Inc.
• Dyne Therapeutics
• BioMarin
• Stealth BioTherapeutics Inc
• Avidity Biosciences
• ReveraGen
• BioPharma, Inc.
• TAIHO PHARMACEUTICAL CO., LTD.
• Akashi RX
• ITALFARMACO S.p.
• NS Pharma, Inc.
• PTC Therapeutics.
• Pfizer Inc.
• FibroGen, Inc.
• SANTHERA PHARMACEUTICALS
• F. Hoffmann-La Roche Ltd

Table of Contents

343 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Global Duchenne Muscular Dystrophy Treatment Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Treatment Type Segment Lifeline Curve
2.8 Market End User Coverage Grid
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel's Model
4.2 Porter's Five Forces Model
4.3 Pricing Analysis
5 Global Duchenne Muscular Dystrophy Treatment Market: Regulations
5.1 Regulations In U.S.
5.2 Regulattions In Europe
5.3 Regulattions In Australia
5.4 Regulations In South Africa
5.5 Regulations In Brazil 69 
6 Market Overview
6.1 Drivers
6.1.1 Increasing Prevalence And Impact Of Duchenne Muscular Dystrophy (Dmd) Disease
6.1.2 Introduction Of Novel Therapies For Dmd Disorder
6.1.3 Rising Awareness For Dmd Treatments
6.1.4 Increase In The Number Of Clinical Trials Is A Recent Trend
6.2 Restraints
6.2.1 Limited Availability Of Dmd Treatments Due To Lack Of Advance Technology
6.2.2 High Treatment Cost Of Dmd Disorder
6.3 Opportunities
6.3.1 Development Of Healthcare Infrastructure And Increasing Investment
6.3.2 Rising Patient Inclination Towards Personalized And Effective Therapies
6.3.3 Strategic Initiatives By The Key Market Players
6.3.4 Support From Patient Advocacy Groups On The Regulatory Approval Process
6.4 Challenges
6.4.1 Lack Of Standardization In Dmd Diagnosis
6.4.2 Ethical Considerations Related To Permanent Alteration Of A Patient's Genetic Code
7 Global Duchenne Muscular Dystrophy Treatment Market, By Treatment Type
7.1 Overview
7.2 Molecular-based Therapies
7.2.1 Antisense Oligonucleotide Therapy
7.2.1.1 Exondys 51
7.2.1.2 Amondys 45
7.2.1.3 Vyondys 53
7.3 Nonsense Mutation
7.3.1.1 Translarna
7.4 Steroid Therapy
7.4.1 Prednisone
7.4.2 Deflazacort
7.5 Others 89 
8 Global Duchenne Muscular Dystrophy Treatment Market, By Therapy
8.1 Overview
8.2 Exon Skipping Approach
8.2.1 Multi-exon Skipping Approach
8.2.2 Single-exon Skipping Approach
8.3 Mutation Suppression
8.4 Dystrophin-targeted Therapies
8.4.1 Gene Therapies
8.4.2 Cell Therapies
8.4.2.1 Gene Editing
8.4.2.2 Gene Addition
9 Global Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration
9.1 Overview
9.2 Parenteral
9.3 Oral
9.4 Others
10 Global Duchenne Muscular Dystrophy Treatment Market, By End User
10.1 Overview
10.2 Hospitals
10.3 Specialty Clinics
10.4 Homecare
10.5 Others
11 Global Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel
11.1 Overview
11.2 Hospital Pharmacy
11.3 Retail Pharmacy
11.4 Online Pharmacy
12 Global Duchenne Muscular Dystrophy Treatment Market, By Region
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 U.K.
12.3.4 Italy
12.3.5 Spain
12.3.6 Russia
12.3.7 Turkey
12.3.8 Belgium
12.3.9 Netherlands
12.3.10 Switzerland
12.3.11 Rest Of Europe
12.4 Asia-pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Australia
12.4.6 Singapore
12.4.7 Thailand
12.4.8 Malaysia
12.4.9 Indonesia
12.4.10 Philippines
12.4.11 Rest Of Asia-pacific
12.5 South America
12.5.1 Brazil
12.5.2 Argentina
12.5.3 Rest Of South America
12.6 Middle East And Africa
12.6.1 South Africa
12.6.2 Saudi Arabia
12.6.3 U.A.E
12.6.4 Egypt
12.6.5 Israel
12.6.6 Rest Of Middle East And Africa
13 Global Duchenne Muscular Dystrophy Treatment Market, Company Landscape
13.1 Company Share Analysis: Global
14 North America Duchenne Muscular Dystrophy Treatment Market, Company Landscape
14.1 Company Share Analysis: North America
15 Europe Duchenne Muscular Dystrophy Treatment Market, Company Landscape
15.1 Company Share Analysis: Europe
16 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, Company Landscape
16.1 Company Share Analysis: Asia-pacific
17 Swot Analysis
18 Company Profiles
18.1 Sarepta Therapeutics, Inc.
18.1.1 Company Snapshot
18.1.1 Revenue Analysis
18.1.2 Company Share Analysis
18.1.3 Product Portfolio
18.1.4 Pipeline Portfolio
18.1.5 Recent Developments
18.2 F. Hoffmann-la Roche Ltd
18.2.1 Company Snapshot
18.2.2 Revenue Analysis
18.2.3 Company Share Analysis
18.2.4 Product Portfolio
18.2.5 Pipeline Portfolio
18.2.6 Recent Developments
18.3 Ptc Therapeutics.
18.3.1 Company Snapshot
18.3.2 Revenue Analysis
18.3.3 Company Share Analysis
18.3.4 Product Portfolio
18.3.5 Recent Development
18.4 Pfizer Inc.
18.4.1 Company Snapshot
18.4.2 Revenue Analysis
18.4.3 Company Share Analysis
18.4.4 Pipeline Portfolio
18.4.5 Product Portfolio
18.4.6 Recent Development
18.5 Akashi Rx
18.5.1 Company Snapshot
18.5.2 Pipeline Portfolio
18.5.3 Recent Developments
18.6 Avidity Biosciences
18.6.1 Company Snapshot
18.6.2 Revenue Analysis
18.6.3 Pipeline Portfolio
18.6.4 Recent Developments
18.7 Biomarin
18.7.1 Company Snapshot
18.7.2 Revenue Analysis
18.7.3 Pipeline Portfolio
18.7.4 Recent Developments
18.8 Capricor Therapeutics, Inc.
18.8.1 Company Snapshot
18.8.2 Pipeline Portfolio
18.8.3 Recent Developments
18.9 Dyne Therapeutics
18.9.1 Company Snapshot
18.9.2 Pipeline Portfolio
18.9.3 Recent Developments
18.10 Fibrogen, Inc.
18.10.1 Company Snapshot
18.10.2 Revenue Analysis
18.10.3 Pipeline Portfolio
18.10.4 Recent Development
18.11 Italfarmaco S.P.A.
18.11.1 Company Snapshot
18.11.2 Pipeline Portfolio
18.11.3 Recent Development
18.12 Ns Pharma, Inc.
18.12.1 Company Snapshot
18.12.2 Pipeline Portfolio
18.12.3 Recent Developments
18.13 Reveragen Biopharma, Inc.
18.13.1 Company Snapshot
18.13.2 Pipeline Portfolio
18.13.3 Recent Development
18.14 Santhera Pharmaceuticals
18.14.1 Company Snapshot
18.14.2 Revenue Analysis
18.14.3 Pipeline Portfolio
18.14.4 Recent Development
18.15 Taiho Pharmaceutical Co., Ltd.
18.15.1 Company Snapshot
18.15.2 Pipeline Portfolio
18.15.3 Recent Developments
18.16 Solid Biosciences Inc.
18.16.1 Company Snapshot
18.16.2 Pipeline Portfolio
18.16.3 Recent Development
18.17 Stealth Biotherapeutics Inc
18.17.1 Company Snapshot
18.17.2 Pipeline Portfolio
18.17.3 Recent Development
19 Questionnaire
20 Related Reports
List Of Tables
Table 1 List Of Prices For Approved Drugs Of The Global Duchenne Muscular Dystrophy Treatment Market
Table 2 Global Duchenne Muscular Dystrophy Treatment Market, By Treatment Type , 2021-2030 (Usd Thousand)
Table 3 Global Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 4 Global Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 5 Global Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 6 Global Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 7 Global Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 8 Global Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 9 Global Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 10 Global Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 11 Global Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 12 Global Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 13 Global Mutation Suppression In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 14 Global Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 15 Global Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 16 Global Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 17 Global Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration , 2021-2030 (Usd Thousand)
Table 18 Global Parenteral In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 19 Global Oral In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 20 Global Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 21 Global Duchenne Muscular Dystrophy Treatment Market, By End Users, 2021-2030 (Usd Thousand)
Table 22 Global Hospitals In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 23 Global Speciality Clinics In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 24 Global Homecare In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 25 Global Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 26 Global Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 27 Global Hospital Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 28 Global Retail Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 29 Global Online Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 30 Global Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 31 North America Duchenne Muscular Dystrophy Treatment Market, By Country, 2021-2030 (Usd Thousand) Country
Table 32 North America Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 33 North America Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 34 North America Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 35 North America Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 36 North America Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 37 North America Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 38 North America Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 39 North America Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 40 North America Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 41 North America Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 42 North America Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 43 North America Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 44 North America Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 45 North America Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 46 North America Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 47 U.S. Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 48 U.S. Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 49 U.S. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 50 U.S. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 51 U.S. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 52 U.S. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 53 U.S. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 54 U.S. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 55 U.S. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 56 U.S. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 57 U.S. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 58 U.S.Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 59 U.S. Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 60 U.S. Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 61 U.S. Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 62 U.S. Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 63 U.S. Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 64 U.S. Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 65 Canada Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 66 Canada Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 67 Canada Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 68 Canada Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 69 Canada Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 70 Canada Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 71 Canada Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 72 Canada Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 73 Canada Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 74 Canada Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 75 Canada Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 76 Canada Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 77 Canada Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 78 Canada Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 79 Canada Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 80 Canada Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 81 Canada Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 82 Canada Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 83 Mexico Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 84 Mexico Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 85 Mexico Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 86 Mexico Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 87 Mexico Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 88 Mexico Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 89 Mexico Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 90 Mexico Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 91 Mexico Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 92 Mexico Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 93 Mexico Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 94 Mexico Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 95 Mexico Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 96 Mexico Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 97 Mexico Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 98 Mexico Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 99 Mexico Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 100 Mexico Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 101 Europe Duchenne Muscular Dystrophy Treatment Market, By Country, 2021-2030 (Usd Thousand)
Table 102 Europe Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 103 Europe Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 104 Europe Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 105 Europe Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 106 Europe Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 107 Europe Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 108 Europe Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 109 Europe Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 110 Europe Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 111 Europe Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 112 Europe Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 113 Europe Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 114 Europe Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 115 Europe Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 116 Europe Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 117 Germany Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 118 Germany Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 119 Germany Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 120 Germany Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 121 Germany Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 122 Germany Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 123 Germany Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 124 Germany Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 125 Germany Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 126 Germany Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 127 Germany Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 128 Germany Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 129 Germany Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 130 Germany Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 131 Germany Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 132 Germany Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 133 Germany Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 134 Germany Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 135 France Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 136 France Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 137 France Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 138 France Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 139 France Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 140 France Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 141 France Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 142 France Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 143 France Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 144 France Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 145 France Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 146 France Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 147 France Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 148 France Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 149 France Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us